Qi Ying-Zi, Jiang Yue-Hua, Jiang Ling-Yu, Shao Lin-Lin, Yang Xue-Song, Yang Chuan-Hua
Health College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Dose Response. 2021 Apr 30;19(2):15593258211011342. doi: 10.1177/15593258211011342. eCollection 2021 Apr-Jun.
It has been proven a close relationship between intestinal microbiota and hypertension. Valsartan is a widely used ARB antihypertensive drug; so far, the effect of valsartan on intestinal microbiota remains largely unexplored. Herein, we evaluated the composition, structure and metabolites of intestinal microbiota of spontaneously hypertensive rats (SHRs) after valsartan administration. In the present study, valsartan administration decreased intestinal microbiota diversity, altered gut microbiota composition, leading to 192 unique OTUs deficiency ( WKY rats) and 10 unique OTUs deficiency ( SHRs) and did not prove impaired intestinal mucosal barriers. Valsartan decreased the production of isobutyric acid and isovaleric acid in SCFAs. Our findings revealed valsartan administration induced far-reaching and robust changes to the intestinal microbiota of SHRs and provided a better understanding of the relationship between efficacy of valsartan and gastrointestinal tract reaction.
肠道微生物群与高血压之间的密切关系已得到证实。缬沙坦是一种广泛使用的ARB类降压药；迄今为止，缬沙坦对肠道微生物群的影响在很大程度上仍未得到探索。在此，我们评估了缬沙坦给药后自发性高血压大鼠（SHRs）肠道微生物群的组成、结构和代谢产物。在本研究中，缬沙坦给药降低了肠道微生物群的多样性，改变了肠道微生物群的组成，导致192个独特OTU缺失（WKY大鼠）和10个独特OTU缺失（SHRs），且未证实肠道黏膜屏障受损。缬沙坦降低了短链脂肪酸中异丁酸和异戊酸的产生。我们的研究结果表明，缬沙坦给药对SHRs的肠道微生物群产生了深远而显著的变化，并为更好地理解缬沙坦疗效与胃肠道反应之间的关系提供了依据。
